Related Experiment Video
Updated: Jan 18, 2026
Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
A Prospective, Real-World, Multicenter Study to Support the Role of Ab-Interno Canaloplasty in Glaucoma Management
Nathan Kerr1, David Lubeck1, Keith Barton1
1From the Centre for Eye Research Australia (N.K.), Melbourne, VIC, Australia; Chicago Arbor Eye Institute (D.L.), Illinois, USA; Moorfields Eye Hospital (K.B.), London, UK; University of Illinois at Chicago (A.A.A.), Illinois, USA; Sydney Eye Hospital (J.C.), Sydney, NSW, Australia; Cataract and Laser Institute (J.S.), Medford, Oregon, USA; Miramichi EyeNB Centre of Excellence (N.S.-H.), Miramichi, NB, Canada; Eye Surgical Associates (S.T.), Lincoln, NE, USA; Eye Physicians and Surgeons of Arizona (S.P.), Glendale, Arizona, USA; University of Montreal (P.A.), Quebec, Canada; McGill University (P.A.), Quebec, Canada; John Moran Eye Center, University of Utah (I.I.K.A.), Utah, USA; Galen Eye Center (H.S.), Ontario, Canada; University of Bonn Eye Clinic (K.M.), Bonn, Germany.
Purpose:
To assess real-world canaloplasty outcomes in glaucoma management using standardized data from an international registry.
Design:
The iTrack Global Data Registry (iTGDR) is an ongoing prospective real-world multicenter observational study on ab-interno canaloplasty with the iTrack or iTrack Advance (Nova Eye Medical), with or without concomitant cataract surgery.
Participants:
Patients diagnosed with ocular hypertension or glaucoma (excluding angle-closure glaucoma).
Methods:
Analysis included eyes with a minimum 12 months follow-up from the iTGDR. Both standalone canaloplasty and canaloplasty combined with cataract surgery were included. Intraocular pressure (IOP) and glaucoma medications were assessed at baseline and postoperative follow-ups. Surgical success was defined according to the 2024 American Academy of Ophthalmology (AAO) criteria.
Main Outcome Measure:
IOP, number of glaucoma medications, and success rate at last follow-up (LFU).
Results:
Two hundred and fifty-four patients (344 eyes) were followed over a mean of 20.5 ± 7.9 months (LFU). Following combined canaloplasty and phacoemulsification (n = 313 eyes), mean IOP and medication usage reduced from 17.2 ± 5.3 mm Hg and 2.1 ± 1.1 preoperatively to 14.1 ± 3.9 mm Hg and 1.3 ± 1.4 at LFU (P < .001); 61.9% of all combined eyes achieved success (increasing to 83% in eyes with baseline IOP > 18 mm Hg), while 43% of eyes became medication-free (vs 7% preoperatively). Standalone canaloplasty (n = 24 eyes) reduced IOP and medication usage from 20.2 ± 7.1 mm Hg and 2.3 ± 0.9 to 15.3 ± 6.3 mm Hg and 1.5 ± 1.6 (P < .01); 35% of eyes achieved success, and 46% of eyes became medication-free (vs none preoperatively). IOP and medication reductions were significant across glaucoma subtypes (primary and secondary open-angle glaucoma, ocular hypertension) and severities (P < .01 for all). The rate of additional glaucoma procedures was 4.9%, including laser procedures; no canaloplasty-related sight-threatening complications were reported. A loss of ≥2 lines of corrected distance visual acuity occurred in 7.3% of eyes, most commonly in association with pre-existing advanced disease or unrelated ocular comorbidities.
Conclusion:
In real-world clinical practice, iTrack canaloplasty significantly reduced IOP and medication burden with a favorable safety profile when performed alone or with phacoemulsification and in diverse glaucoma populations.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
01:25Glaucoma: Overview